CLAIMS

1. A process for preparing an improved dialysis fluid formulation, the process comprises: preparing a composition comprising KLVFF peptide, or a variant thereof, as the capturing and binding agent, and a carrier therefor; and mixing said composition with a dialysate solution.

2. The process according to claim 1, wherein the variant includes FFVLK peptide which is a reverse analog of KLVFF peptide.

3. The process according to claim 1, wherein the capturing and binding agent, or one of its derivatives, is brought into dosage form together at least one solid, liquid, or semi-liquid carrier and/or auxiliary substance.

4. The process according to claim 1, wherein the capturing and binding agent is a tetramer peptide containing four copies of the monomer peptide in reverse sequence, as shown below:



5. The process according to claim 4, wherein the tetramer capturing and binding agent is linked, through its cys side chain, to an 8-arm polyethylene glycol maleimide to form a molecule of the capturing and binding agent with 32 Beta-Amyloid capturing arms.

CLAIMS

1. A process for preparing a dialysate solution for use in the treatment of a pathological condition associated with the induction of Beta-Amyloid level in a subject, said process comprising:

   preparing a composition comprising KLVFF peptide or a variant thereof, as the capturing and binding agent, and a carrier therefor; and

   mixing said composition with a dialysis buffer solution,

   wherein the KLVFF peptide or variant thereof consists of three or more amino acid sequences which are linked together through a linker with three to eight capturing arms, and wherein each of said capturing arms is linked to an amino acid sequence, and said carrier is a poly(ethylene glycol) cross-linker carrier gel.

2. The process according to claim 1, wherein the variant includes FFVLK peptide which is a reverse analog of KLVFF peptide.

3. The process according to claim 1, wherein the capturing and binding agent, or one of its derivatives, is brought into dosage form together with at least one solid, liquid, or semi-liquid carrier and/or auxiliary substance.

4. The process according to claim 1, wherein the capturing and binding agent is a tetramer peptide containing four copies of the monomer peptide in reverse sequence, as shown below:



5. The process according to claim 4, wherein the tetramer capturing and binding agent is linked, through its cys side chain, to an 8-arm polyethylene glycol maleimide to form a molecule of the capturing and binding agent with 32 Beta-Amyloid capturing arms.